Novo’s Weight-Loss Drug Demand Fuels Rise in Illegal Sales
- Danish Medicines Agency reports 26 websites to police
- Illicit sale of Wegovy, Ozempic increases amid high demand
Packets of Novo Nordisk’s Ozempic.
Photographer: Carsten Snejbjerg/BloombergThis article is for subscribers only.
Growing demand for Novo Nordisk A/S’s weight-loss and diabetes drugs is fueling a rise in illegal sales in its home country of Denmark, where authorities are now seeking to clamp down on the illicit activity.
The Danish Medicines Agency has reported to police 26 websites which claim to sell products such as Novo’s Ozempic and Wegovy as well as potency drugs. The websites aren’t approved to sell medicines and there are no guarantees the products are legitimate, the agency said in a statement.